Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Oct 29, 2021 12:13pm
113 Views
Post# 34063780

RE:What I've learned from Vicenza this week...

RE:What I've learned from Vicenza this week...
SouthernTierTom wrote: Before I begin, I want to thank Dr. Ronco for hosting, it was the most "Spectral-centric" ( even if it just means hearing our name ) session I've witnessed in the 39 years of Vicenza "EXCELLENCE"..I hope Marla took good notes.

1) Based on the divulgence of EAA ( endotoxin activity assay - EDT wholly owned and FDA approved since 2003 )  use  ( every 6 hours and well BEFORE .6 ) AND his persistent belief that PMX is INDEED an effective tool in the fight against Covid19, I am "personally" placing Dr. Ronco in my top .0028% ( and perhaps higher based on an ongoing "data dive" ) of global sepsis experts...you, your team and Italy as a whole are to be commended for your research and care!

2) Dr. Sylvia De Rosa is a wonderful lady with massive amounts of knowledge in the area of PMX and the EAA - Bravo doctor...and thank you!

3) Based upon the numbers now being shared, endotoxin is playing a MUCH larger role in sepsis than we were initially led to believe ( time for MM to update his numbers )

4) It would have been a good idea to have understood the capacity of the PMX filter as it pertains to endotoxin absortion prior to starting the phase 3 Euphrates Trial.  Given both the PMX filter and the EAA were jointly invested in 1994, it was disappointing that somebody didn't recognize this as an importnt variable prior to trial initiation.

5) Based on the simplicity and highly effective ability of the EAA FDA approved diagnostic...why haven't clinicians been using this around the globe in helping to decide how aggressively a patient should be treated or at the least "monitored" for severe illness? Afterall, it has been fully FDA approved since 2003 and even "commoners" here on the "stock escort network" have been curiously wondering why we can't seem to sell ANYTHING..including this most important tool to guide knowledge and potential care for North American and patients around the globe?

Later today I will offer a post from another "commoner" that actually predicted on the morning of October 3rd 2016 ( just minutes after the Beech Boys presented the top-line data to the sheep) that ONLY 179 patients of the advertised 450 patients mattered..."how could he/she/other know it"? 

Wait for it..it is an EPIC example of just why "everyone's opinion" sometimes counts ; - )

Bon appetito,
T


1) I currently have Dr Ronco at .0009%

2) Agreed

3) I'm still trying to sort out all of Kellum's stats and claims.  But suffice it to say that the revenue opportunity (target market) seems to be much higher than they are letting on in the investment deck.

4) dosage in an under-talked about issue.  Several (ongoing) studies have (are) addressing this.  I believe, when it is all sorted out, there will be ways to help the >.9 crowd with PMX filters...and of course that comes with even higher future revenue potential for Spectral.

5) HUGE miss in the medical triage arena IMO.  EAA should be in extensive use in every ICU in the world...espcially with 5M Covid deaths so far and an annual rate of 10 million Septic shock deaths (not including Covid).  And we haven't even talked about antibiotic resistant bacteria and the over prescribing of antibiotics - which will eventually exacerbate the problem of bacterial infections...which may lead to many more cases where PMX is the ONLY treatment available.

MM



<< Previous
Bullboard Posts
Next >>